Loading...
•
Mar 31, 2021
Alnylam Q1 2021 Earnings Report
Alnylam reported strong commercial performance and advanced Vutrisiran towards the market.
Key Takeaways
Alnylam Pharmaceuticals reported first quarter 2021 financial results, achieving combined net product revenues of $136 million for ONPATTRO, GIVLAARI, and OXLUMO. The company also advanced Vutrisiran towards the market with positive results from the HELIOS-A Phase 3 study and submission of a New Drug Application with the U.S. Food and Drug Administration.
Achieved First Quarter 2021 Combined Net Product Revenues of $136 Million for ONPATTRO®, GIVLAARI®, and OXLUMO®
Advanced Vutrisiran toward Market with Positive Results from HELIOS-A Phase 3 Study and Submission of New Drug Application (NDA) with U.S. Food and Drug Administration (FDA)
Launched “Alnylam P5x25” Strategy to Deliver Transformative Rare and Prevalent Disease Medicines for Patients Around the World Through Sustainable Innovation and Exceptional Financial Performance
Provided Enrollment Update on HELIOS-B Phase 3 Study of Vutrisiran and Now Expects to Complete Enrollment in Late 2021, Ahead of Previous Expectations
Alnylam
Alnylam
Alnylam Revenue by Segment
Revenue by Segment
ONPATTRO Revenue
CapyFin.comGIVLAARI Revenue
CapyFin.comOXLUMO Revenue
CapyFin.com Forward Guidance
Alnylam reiterated its full year 2021 financial guidance.
Positive Outlook
- Combined net product revenues for ONPATTRO, GIVLAARI and OXLUMO between $610 million and $660 million
- Net revenues from collaborations and royalties between $150 million and $200 million
- GAAP R&D and SG&A expenses between $1,335 million and $1,455 million
- Non-GAAP R&D and SG&A expenses between $1,175 million and $1,275 million
- Excludes $160-$180 million of stock-based compensation expenses from estimated GAAP R&D and SG&A expenses
Revenue & Expenses
Visualization of income flow from segment revenue to net income